Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Astrocytoma (grade III) are frequently mutated in isocitrate dehydrogenase (IDH1). 31039537 2019
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE We here report neuroimaging findings in a 69-year-old man with a "butterfly" pattern on dynamic FET [O-(2-[F]-fluoroethyl)-L-tyrosine] PET and the diagnosis of an anaplastic astrocytoma (WHO grade III; IDH-1/-2 wildtype, no 1p/19q co-deletion) but without typical MRI contrast enhancement. 31348085 2019
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma. 31371189 2019
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE An important underlying observation was that patients with anaplastic astrocytomas (AA) without IDH mutation had a clinical course similar to that of patients with glioblastomas (GBM). 31623667 2019
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Mutated IDH1 R132H protein was expressed in 2 GBM from adult patients with previous supratentorial anaplastic astrocytoma. 30203362 2018
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Multivariate analysis demonstrated that T2-EOR (HR 3.28; 95% CI 1.22-8.81; p = 0.0192) and IDH1 mutation (HR 3.90; 95% CI 1.53-10.75; p = 0.0044) were predictive of survival in patients with AA and AOA. 28885120 2018
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. 30072066 2018
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE 33-year-old nulligravid woman with newly diagnosed anaplastic astrocytoma (AA; WHO grade III, IDH1-negative) sought fertility preservation. 29739361 2018
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE The histopathologic examination confirmed a leptomeningeal spread of a K27M-mutated anaplastic astrocytoma (WHO° III) without R132H-IDH1 mutation. 29066318 2018
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 ± 14 years) and used to extract individual level, gray matter connectomes. 27848136 2017
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status. 28110298 2017
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3). 28851427 2017
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. 28640702 2017
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE Among IDH1-mutated astrocytomas no significant difference in survival was shown between DA and AA. 28214203 2017
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas. 27626492 2016
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE A second surgery was performed, and pathology demonstrated recurrent tumor, consistent with IDH1-mutated anaplastic astrocytoma. 26911558 2016
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma. 26443480 2016
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. 25962792 2015
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE The JHH-273 model is characteristic of anaplastic astrocytoma and represents a valuable tool for investigating the pathogenesis of this distinct molecular subset of gliomas and for preclinical testing of compounds targeting IDH1 mutations or alternative lengthening of telomeres. 25471051 2015
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. 24748470 2014
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE We sought to determine the impact of surgical resection on survival after controlling for IDH1 status in malignant astrocytomas-World Health Organization grade III anaplastic astrocytomas and grade IV glioblastoma. 24305719 2014
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 GeneticVariation disease BEFREE IHC detected the IDH1 mutation in 72% (13/18) anaplastic astrocytomas and 30% (3/10) astrocytomas; however, it failed to detect the mutation in 258 thyroid, 11 renal cell, 10 ovarian, 18 endometrial, 20 breast, 25 colorectal, 22 non-small cell lung carcinoma, 25 melanomas, and 8 thyroid follicular adenomas. 23235339 2014
CUI: C0334579
Disease: Anaplastic astrocytoma
Anaplastic astrocytoma
0.400 Biomarker disease BEFREE Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. 24777756 2014